Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Chimeric antigen receptor T-cell (CAR-T) therapies are standard of care for the treatment of several hematologic malignancies. Although patients receiving CAR-T therapies are frequently hospitalized ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...